Medit J Hemat Infect Dis 2010; 2(2); Open Journal Sy MEDITERRANEAN JOUR Perspectives Role of Allogeneic Transpla Drugs Benedetto Bruno, Luisa Giaccone, Mor Division of Hematology at the S. Giov Italy. Correspondence to: Benedetto Bruno, M Giovanni Battista, Via Genova 3, 10126, TO Competing interests: The author have Published: June 1, 2010 Received: May 10, 2010 Accepted: May 31, 2010 Medit J Hemat Infect Dis 2010, 2(2): e2010013, This article is available from: http://www.mjhid This is an Open Access article distri (http://creativecommons.org/licenses/by/2.0 ), w the original work is properly cited. Abstract High-dose melphalan with autolo care for patients with newly diag development of agents with poten bortezomib has further improved continuous risk. Allografting is a potentially curat its well documented graft-vs-myel though molecular remissions hav conditionings, their applications, g relapsed/refractory patients. Th introduction of non-myeloablative The introduction of new drugs, ch to define role and timing of an benefit from graft-vs-myeloma effe Ultimately, new drugs should not be employed to achieve profoun effects as consolidation/maintena should be explored only in well-de Introduction: Multiple myeloma is a cell disorder, though recent advan understanding of its pathogenesis h peculiar mechanisms that have becom ystem RNAL OF HEMATOLOGY AND INFECTIOU www.mjhid.org ISSN 2035-3006 antation in Multiple Myeloma in the reno Festuccia and Mario Boccadoro. vanni Battista Hospital, University of Torino, Via G M.D., Ph.D., Divisione Universitaria di Ematologia, Azien ORINO, Italy, Phone +39-011-6334354 E-mail: benedetto e declared that no competing interests exist. , DOI 10.4084/MJHID.2010.013 d.org/article/view/5944 ibuted under the terms of the Creative Commons which permits unrestricted use, distribution, and reproduction in a ogous stem cell rescue has been regarded as gnosed myeloma up to the age of 65-70 yea nt anti-tumor activity such as thalidomide, le d overall survival and response rates. Howev tive treatment for a subset of multiple myelo loma effects. However, its role has been hotly ve been reported up to 50% after high-dose given the high toxicity, have been for long lim hese limitations have greatly been reduce e/reduced-intensity conditionings. haracterised by low risks of early mortality, allograft to capture the subset of patients ects. be viewed as mutually exclusive with an allog nd cytoreduction before and enhance graft- ance therapy after an allograft. However, th esigned clinical trials. fatal plasma nces in the has identified me targets of agents with potent anti-myeloma lenalidomide and bortezom chemotherapy and autologous with/without these newer agents h US DISEASES e Era of New Genova 3, Torino, nda Ospedaliera San o.bruno@unito.it Attribution License any medium, provided the standard of ars. The recent enalidomide and ver, relapse is a oma patients for y debated. Even e myeloablative mited to younger ed through the indeed requires who may most graft. They may -versus-myeloma his combination a activity such as mib. High-dose s transplantation has been regarded